Novo ​Nordisk plans ‌to seek Chinese ​regulatory ​approval for its ⁠weight-loss ​pill "very soon," ​CEO Mike Doustdar said ​Tuesday, ​in a move ‌to ⁠catch up with rival ​Eli ​Lilly ⁠in the ​world's ​second-largest ⁠pharmaceutical market.